Lonza Introduces Risk Assessment Platform for Biopharmaceuticals - - BioPharm International

ADVERTISEMENT

Lonza Introduces Risk Assessment Platform for Biopharmaceuticals


Early risk assessment has become a crucial factor in biopharmaceutical drug development programs. To address this growing market need, Lonza launched a Developability Assessment Platform that is designed to reduce attrition rates and improve the ranking of early drug candidates, according to a press release. The prediction tools include a suite of in silico-based services that assess candidates for fitness for large-scale manufacture (manufacturability) and immunogenicity profiles in humans (safety).

The manufacturability assessment service analyzes chemical degradation pathways and post-translational modifications, including deamidation, oxidation, and glycosylation, as well as potential physical stability issues, such as protein aggregation. The safety assessment service uses Lonza’s proprietary Epibase in silico screening tool to identify potential T-cell epitopes in target proteins that may trigger potential immune reactions in human studies.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
Author Guidelines

Click here